source: dysrhythmias identified by pattern and origin supraventricular atrial junctional...

47

Upload: sara-daniel

Post on 26-Dec-2015

237 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?
Page 2: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Source: http://www.rnceus.com/ekg/ekghowto.html

Page 3: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Dysrhythmias

• Identified by pattern and origin• Supraventricular

• Atrial

• Junctional

• Ventricular

• Manifestations?

Page 4: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Fast Channel Action Potential

Page 5: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Slow Channel Action Potential

Page 6: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Goals of Dysrhythmic Therapies

• Decrease symptoms

• Prolong survival

Achieved by

Slowing rate of conduction

Decreasing automaticity

Increasing refractory period

Page 7: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Classes of Dysrhythmic Drugs

• Class I—Sodium Channel Blockers

• Class II—Beta Blockers

• Class III—Potassium Channel Blockers

• Class IV—Calcium Channel Blockers

Page 8: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Class I Sodium Channel Blockers

• Depress phase 0

• Block sodium through fast channel

• Slow conduction velocity (SA to AV nodes)

• Prolong refractory period

• Reduce automaticity

• Subclasses based on action in refractory period

Page 9: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Sodium Channel BlockerProcainamide (Procan, Procanbid, Pronestyl)• MOA: blocks sodium channels in myocardial cells, reducing

automaticity and slowing conduction

• Indications: acute/chronic atrial and ventricular dysrhythmias

• Contraindications: AV block, severe CHF, blood dyscrasias, MG; caution in hepatotoxicity

• Side Effects: n/v, HA, abdominal/joint pains (lupus-like syndrome); significant anticholinergic effects

• Assessment/Monitoring: EKG, VS, drug levels, weight, edema, I/O, CBC, electrolytes, BUN/Cr, LFTs, bowel/bladder status, eye pain

• Education: give NSAIDs for joint pains; report weight increase, edema, SOB, fever, syncope, jaundice, eye pain, sxs of stroke, increase fluid/fiber intake; no ETOH or stimulants; don’t skip dose

Page 10: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Other Class I Drugs

• Ia—Quinidine (Diarrhea, tinnitus)• Ib

• Lidocaine* (DOC for ventricular dysrhythmias)• Mexiletine (Mexitil)• Phenytoin (Dilantin)—for Digoxin toxicity

• Ic—most likely to CAUSE arrhythmias• Flecanide (Tambocor)• Propafenone (Rhythmol)

Page 11: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Can local lidocaine given as an Can local lidocaine given as an anesthetic affect the heart?anesthetic affect the heart?

Page 12: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Class IIBeta Adrenergic Blockers

Page 13: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Class IIBeta Blockers

• Decrease automaticity, HR• Decrease input to sinus node

• Block epinephrine, NE in CNS

• Decrease polarization through Purkinge fibers

• Increase refractory period

• Decrease risk of sudden cardiac death

• Primarily supraventricular dysrhythmias

Page 14: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Beta BlockerPropranolol (Inderal)

• MOA: blocks epi, NE at beta-1 & 2 receptors, reducing HR, conduction, velocity; lowers BP

• Indications: primarily SVT, or stress-induced, HTN, angina, prevention of MI, hypermetabolic states; glaucoma, migraines

• Contraindications: cardiogenic shock, bradycardia, heart blocks, heart failure, asthma, COPD; caution in DM

• Side Effects: hypotension, bradycardia, fatigue, depression, sexual dysfunction, hypoglycemia (DM)

• Assessment/Monitoring: VS, EKG, weight, I/O, mood, glucose, lungs, safety

• Education: check HR, BP, weight, report SOB, chest pain, weight gain, edema, syncope (safety), sxs of stroke, depression or ED, DO NOT DISCONTINUE

Page 15: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Class IIIPotassium Channel BlockersClass IIIPotassium Channel Blockers

Page 16: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Class IIIPotassium Channel Blockers

• Prolongs phase 3 of FA potential

• Slows repolarization

• Reduce automaticity

• Used in life-threatening arrhythmias

• Most likely to cause arrhythmias

• Less ventricular fibrillation than Class I

Page 17: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Potassium Channel BlockerAmiodarone (Cordarone)

• MOA: block potassium channels, prolongs refractory period, slows repolarization; also blocks sodium channels

• Indications: resistant, life-threatening V tach

• Contraindications: severe bradycardia, cardiogenic shock, heart blocks; caution in heart failure, hepatic disease

• Side Effects: ARDS, thyroid disorders, blurred vision, n/v, anorexia, fatigue, syncope; skin discoloration

• Assessment/Monitoring: VS, EKG, lungs/CXR/PFTs, TFTs, digoxin and warfarin levels

• Education: hold for HR < 60; report chest pain, palpitations, syncope, SOB, sxs of thyroid dx: monitor weight, I/O, edema, sxs of hepatotoxicity; take with food; wear sun-screen

Page 18: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Additional Class III

• Bretyllium (Bertylol)

• Dofetilide (Tikosyn)

• Ibutilide (Covert)

• Sotolol (Betapace)

Page 19: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Class IV

Calcium Channel Blockers

Class IV

Calcium Channel Blockers

Page 20: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Class IVCalcium Channel Blockers

• Slow automaticity in SA node

• Slowed impulse conduction through AV node

• Prolonged refractory period

• Only for supraventricular dysrhythmias

Page 21: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Calcium Channel BlockerVerapamil (Calan)

• MOA: slows calcium ions in myocardial cells and vascular smooth muscle; slows conduction velocity

• Indications: HTN, angina, supraventricular dysrhythmias

• Contraindications: hypotension, heart block, bradycardia

• Side Effects: hypotension, bradycardia, HA, constipation

• Assessment/Monitoring: VS, BP, EKG, weight, I/O, sxs of HF, bowel status

• Education: hold for syncope or HR < 60; report SOB, chest pain, weight gain, edema, syncope (safety), sxs of stroke; don’t take with GF juice; do not break/chew SR tablets, increase fiber, DO NOT DISCONTINUE

Page 22: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Additional Calcium Channel Blockers

• Diltiazem (Cardizem)

• Adenosine (Adenocard)—PSVT

• Nifedipine (Procardia)—selective for vasculature

Page 23: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Nursing Implications with Antidysrhythmic Drugs

• Any drug that prevents or corrects a dysrhythmia is capable of causing a dysrhythmia.

• Patients, especially on Class I and Class III need to be closely monitored.

Page 24: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

RB is a 74 yo male with recent CABG x 3. During the post-op period he developed PVCs and A fib. He is started on a lidocaine drip to control PVCs. What should you monitor?

While receiving IV lidocaine, RB’s HR decreases to 52 with continued PVCs. What should you do?

Page 25: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

RB is now in NSR. The MD prescribes amiodarone 200 mg po daily. Why is he getting this drug and what should be monitored?

Page 26: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

RB needs more instruction regarding amiodarone when stating

1. “I will take 2 tablets, if I miss a dose.”

2. “I will report fatigue.”3. “I will check my pulse

before taking the pills.”4. “I should use decaffeinated

coffee.”

Page 27: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Additional Dysrhythmic Drugs

• Digoxin (Lanoxin)• Decreases automaticity in SA node

• Slows conduction through AV node

• Supraventricular dysrhythmias

• Phenytoin (Dilantin); for Digoxin toxicity

• Magnesium sulfate (torsades de pointes)

Page 28: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

How do we know these drugs are working?

How do we know if they aren’t?

Page 29: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Nursing Intervention

• Screening?• What will will monitor?• Monitor which organs?• Monitor which electrolytes?• Interactions?• Signs of success?• Signs of failure?• Side-effects?• Safety?

Page 30: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

All of the following indicate improvement in cardiac status, except

1. Decreased pulse deficit

2. Syncope

3. Weight loss

4. Lungs CTA

Page 31: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Causes of Shock

• Hypovolemic

• Neurogenic

• Cardiogenic

• Anaphylactic

• Septic

Page 32: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Initial Key Steps

• Lay flat with feet elevated

• Keep warm

• Get help

• Call physician

• Initiate IVFs

• Oxygen

• Prepare for code

Page 33: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

IV Fluid Replacement

• Crystalloids• Normal Saline (NS)

• Lactated Ringer’s Solution (LR)

• Plasmalyte

• Colloids• Albumin

• Hetastarch

• Dextran

• Plasma Protein Fraction

Page 34: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Colloidal Fluid ReplacementAlbumin (Albuinar, Albutein, Buminate, Plasbumin)

• MOA: maintains plasma oncotic pressure in vasculature

• Indications: restore plasma volume in hypovolemic shock or restore proteins in hypoproteinemia

• Contraindications: severe heart failure

• Side Effects: allergy, fluid overload

• Assessment/Monitoring: VS/PO, lungs, I/O, weight, edema, sxs of anaphylaxis

• Education: report SOB, wheezing, palpitations, edema

Page 35: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Additional Colloids

• Plasma Protein Fraction (Plasmanate)

• Dextran 40 (Gentran, Macrodex)

• Hetastarch (Hespan)

Page 36: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

The client at greatest risk from fluid

overload is...

1. 36 yo with sepsis

2. 68 yo with CHF

3. 70 yo with HTN

4. 70 yo with CRF

Page 37: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Vasoconstrictor (Sympathomimetic)Norepinephrine (Levarterenol, Levophed)

• MOA: alpha-1* and beta-1 agonist

• Indications: acute shock (septic) and cardiac arrest

• Contraindications: hypovolemic shock; caution in ischemic disease

• Side Effects: HTN, reflex bradycardia, dysrhythmias, organ ischemia

• Assessment/Monitoring: VS, EKG, organ fx, glaucoma, IV patency, HA, CRT

• Education: report chest pain, palpitations, SOB, eye pain, IV pain, HA

Page 38: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Other Vasoconstrictors

• Isoproterenol (Isuprel); alpha & beta*

• Phenylephrine (Neosynephrine); alpha

• Mephentermine (Wyamine); alpha & beta

Page 39: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

The priority nursing action for a client about to receive Levophed for hypovolemic shock

is...

1. Evaluate IV access

2. Measure baseline HR & BP

3. Measure urine output

4. Obtain weight

Page 40: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Perfusion can be evaluated by all, except

1. Vital signs

2. Weight

3. Output

4. CRT

Page 41: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

The nurse knows that all are true, relating to NE, except

1. NE should be stopped immediately after BP stabilizes

2. NE may cause organ failure

3. NE requires telemetry

4. NE may aggravate glaucoma

Page 42: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Inotropic AgentDopamine (Dopastat, Inotropin)

• MOA: stimulates dopamine receptors in kidney (activates renin/angiotensin); beta 1 agonist at moderate doses; alpha 1 at high doses

• Indications: maintain renal perfusion, increase CO, shock

• Contraindications: pheochromocytoma, ventricular fibrillation

• Side Effects: dysrhythmia, HTN, tissue necrosis at IV site

• Assessment/Monitoring: VS, EKG, I/O, weight, edema, sxs of HF, CRT, HA, IV site

• Education: report chest pain, palpitations, SOB, pain at IV site, cold/numb extremeties, HA; ICU protocols

Page 43: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Other Inotropic Agents

• Digoxin (Lanoxin)

• Dobutamine (Dobutrex); beta 1

Page 44: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

The treatment for dopamine

extravasation is...

1. Atropine

2. Narcan

3. Neostigmine

4. Regitine

Page 45: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Anaphylaxis Drug (Sympathomimetic)Epinephrine (Adrenalin)

• MOA: non-selective sympathomimetic

• Indications: anaphylaxis

• Contraindications: caution in HTN, CVA, CAD, glaucoma, dysrhythmias, organ ischemia, hyperthyroidism

• Side Effects: HTN, dysrhythmias, organ ischemia

• Assessment/Monitoring: VS, EKG, lungs, I/O, CRT, organ perfusion, MS

• Education: report SOB, chest pain, palpitations, cold/numb extremities, anxiety; ICU protocols; injection techniques, reasons for test doses

Page 46: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Additional Drugs for Anaphylaxis

• Antihistamines (-amines)

• Beta 2 agonists (-terols)

• Steroids (-sones)

Page 47: Source:  Dysrhythmias Identified by pattern and origin Supraventricular Atrial Junctional Ventricular Manifestations?

Key Points for Shock

• Correct hypovolemia before using vasoconstrictors or inotropics

• All drugs given on infusion pumps

• Telemetry required

• Almost all drugs have short ½ life (x digoxin)

• Most have potential to cause tissue damage if extravasation occurs

• All can compromise organ function